ASTRO 2022 | The impact of stereotactic body radiation therapy on outcomes in NSCLC

Kevin Stephans, MD, Cleveland Clinic, Cleveland, OH, discusses the impact of stereotactic body radiation therapy (SBRT) dose on outcomes in non-small cell lung cancer (NSCLC), with consideration to tumour histology. Dr Stephans also discusses possible risk factors for disease recurrence. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.